NCT00498407View on ClinicalTrials.gov

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Advanced Colorectal CancerColorectal Cancer
Interventions
DRUG

CP-4055

CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion

Trial Locations (4)

AB25 2ZN

Aberdeen Royal Infirmary, Foresterhill,, Aberdeen

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

LEI 5WW

Medical Oncology Dept. of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary, Leicester

HA6 2RN

Macmillan Lead Clinician in Gastro-intestinal Cancer Mount Vernon Cancer Centre, Northwood

Sponsors

Lead Sponsor

Clavis Pharma
All Listed Sponsors
lead

Clavis Pharma

INDUSTRY

NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter